NeOnc Technologies Secures FDA Approval for NEO212 Trials
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company dedicated to innovative therapies for central nervous system (CNS) cancers, has reached a significant milestone. The U.S. Food and Drug Administration (FDA) has granted authorization for the company to advance to the Phase IIa/IIb clinical trial of its leading therapeutic candidate, NEO212.
This pivotal authorization follows a successful Phase I dose-escalation study. That study highlighted the safety of administering NEO212, with patients able to tolerate doses of up to 810 mg daily during the first five days of a 28-day treatment cycle. As further evaluations continue, NeOnc anticipates initiating patient enrollment for Phase II in the near future.
A Transformative Chemotherapy Breakthrough
NEO212 stands out as the first oral chemical conjugated chemotherapy developed by NeOnc Technologies. It combines Temozolomide (TMZ), which remains the current treatment standard for glioblastoma and other brain malignancies, with NEO100. This proprietary compound, perillyl alcohol (POH), aims to address the shortcomings of TMZ, such as treatment resistance and limited reach into the brain.
The innovative formulation of NEO212 is set to significantly enhance drug delivery through the blood-brain barrier. NeOnc believes that NEO212 has the potential to supplant TMZ, transforming the treatment landscape for conditions like glioblastoma and astrocytoma, and providing hope for many patients facing these aggressive cancers.
Expanding Clinical Trials and Patient Enrollment
The rollout of the NEO212-01 Phase II trial will see an expansion of patient enrollment at leading cancer treatment centers across the nation. Currently, four sites have received approval to conduct the trial:
Participating Institutions
- NextGen Oncology – Kumar Sankhala, MD
- Northwest Medical Specialties (NWMS) – Jorge Chaves, MD
- Oncology Physician’s Network – Vu Phan, MD
- University of Southern California (USC) – Frances Chow, MD
To optimize the potential for patient recruitment, NeOnc is in the process of collaborating with a broad array of prestigious cancer institutions.
Anticipated sites for the expanded Phase II enrollment include Baylor Scott & White, Beverly Hills Cancer Center, Cancer Specialists of North Florida, and other notable centers across the U.S., all aimed at maximizing patient access to this groundbreaking therapy.
Insights from NeOnc Leadership
Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies, commented on this significant advancement, stating, “Receiving FDA authorization to move NEO212 into Phase II is a defining moment for our company. This project encapsulates years of dedication and innovation, merging our proprietary NEO100 with Temozolomide to create an impactful treatment that could redefine brain cancer therapies.”
Expounding on this sentiment, Dr. Thomas Chen, Chief Executive Officer and Founder of NeOnc Technologies, added, “Our mission is to instill genuine hope in brain cancer patients and their families amidst a landscape often lacking effective options. NEO212 represents this vision, intertwining science with compassion. Transitioning into Phase II transcends mere regulatory progress; it embodies a pivotal leap toward reshaping brain cancer care globally.”
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is at the forefront of developing remarkable therapies for CNS tumors and other challenging cancers. The company's portfolio includes innovative products like NEO100 and NEO212, all underpinned by robust intellectual property aimed at delivering significant positive outcomes for patients worldwide.
Frequently Asked Questions
What is NEO212?
NEO212 is an oral chemotherapy candidate developed by NeOnc Technologies, designed to treat brain cancer by overcoming the limitations of existing treatments like Temozolomide.
What FDA approval did NeOnc Technologies receive?
The FDA authorized NeOnc to begin Phase II clinical trials for its innovative treatment NEO212.
How does NEO212 differ from Temozolomide?
NEO212 combines Temozolomide with a proprietary drug component, ensuring better penetration of the blood-brain barrier and improving treatment efficacy.
What conditions can NEO212 potentially treat?
NEO212 could potentially treat various brain cancers, including glioblastoma and astrocytoma, offering new hope for patients with aggressive conditions.
How can patients enroll in the NEO212 trial?
Enrollment for the NEO212 trial is expected to begin soon, with information available through the participating clinical trials at major cancer centers.
